Please login to the form below
UniQure
This page shows the latest UniQure news and features for those working in and with pharma, biotech and healthcare.
FDA removes clinical hold on uniQure’s haemophilia gene therapy
In a statement, uniQure said that the patient diagnosed with HCC had ‘multiple risk factors’ associated with this type of cancer. ... UniQure added that all patients in its haemophilia clinical programme have abdominal ultrasounds performed one year
Latest news
-
UK’s CMA clears Roche’s $4.3bn takeover of Spark
Athough, analysts at Jefferies have previously suggested that with a number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
-
Roche moving closer to approval of Spark takeover; report
number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
-
Roche reveals yet another Spark takeover delay
Analysts at Jefferies have suggested that is unlikely to be the case, given that a number of other companies are developing haemophilia gene therapies including BioMarin, Sangamo and UniQure which all
-
ACPs to lead gene therapies in haemophilia market growth
BioMarin’s ValRox, which is expected to launch as early as 2020, and Spark Therapeutics’ SPK-8011 for haemophilia A, and uniQure’s AMT-061 and Pfizer/Spark Therapeutics’ SPK-9001
-
New results back Sangamo, UniQure haemophilia gene therapies
Encouraging results for firms in four-way race. Sangamo and UniQure have continued to build the case for their one-shot gene therapies for haemophilia A and B, with new data ... uniQure thinks spontaneous bleeds decrease substantially when FIX activity
More from news
Approximately 13 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Gene therapy failures. The industry and Europe’s healthcare systems are wary of that magic one million threshold, thanks to the failure of the first ever gene therapy, UniQure’s Glybera. ... The success or failure of Bluebird will be closely watched
-
Bluebird Bio: on the cusp of a gene therapy revolution
success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... The EMA approved the world’s first ever
-
Rare diseases: meeting the challenge
Unfortunate message. Some of these thorny problems were encapsulated in uniQure’s recent decision not to seek an extension to its five-year European marketing authorisation - which expires in October - for
-
Pharma deals in April 2015
BMS will also take a 4.9% equity stake in uniQure which will cost around $32m, with another 5% ownership scheduled before the end of the year (at 10% premium). ... UniQure also stands to receive research, development and regulatory milestones, including
-
Medius Deal Watch table for April 2015
32, 700. uniQure NV/ Bristol-Myers Squibb. R&D collaboration plus equity investment.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Therachon appoints Christian Meyer as chief medical officer
Meyer joins the biotech from uniQure B.V where he was chief medical officer and has held several similar roles for Cardoz, Symphogen, Zymenex and Novo Nordisk.
-
uniQure appoints chief executive officer
Based in the Netherlands and the US, uniQure has appointed Matthew Kapusta as its chief executive officer. ... This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals.
-
Basilea's Hans Christian Rohde takes up commercial role at uniQure
Will serve as gene therapy specialist's chief commercial officer. Gene therapy company uniQure has appointed Hans Christian Rohde to serve as its new chief commercial officer. ... In his new role at Netherlands-based uniQure he will be tasked with
More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Solaris Health looks at the gene therapy revolution
There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
- Medscape Education Receives Joint Accreditation with Commendation to Deliver Continuing Education for Healthcare Providers
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
- NHS England to roll out continuous glucose monitors to all those with type 1 diabetes
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
- WHO launches funding appeal for greater Horn of Africa prompted by food crisis
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- Animation: Living With
- The journey from the patient's perspective...
- Achieving communication excellence by targeting the right channel at the right time
- By Danny Buckland...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
